Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

China · Delayed Price · Currency is CNY

8.08

-0.13 (-1.58%)

Aug 14, 2026, 3:00 PM CST

-29.62% (1Y)

Market Cap	13.04B -29.7%
Revenue (ttm)	4.03B +6.0%
Net Income	585.83M -20.2%
EPS	0.36 -18.4%
Shares Out	1.61B
PE Ratio	22.58
Forward PE	12.63
Dividend	0.10 (1.24%)
Ex-Dividend Date	Jun 9, 2026

Volume	9,046,453
Open	8.19
Previous Close	8.21
Day's Range	8.07 - 8.27
52-Week Range	6.72 - 11.92
Beta	0.36
Analysts	Buy
Price Target	11.77 (+45.67%)
Earnings Date	Aug 28, 2026

About SHA:603707

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injec... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 1,558

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603707

Full Company Profile

Financial Performance

In 2025, SHA:603707's revenue was 3.99 billion, an increase of 1.71% compared to the previous year's 3.92 billion. Earnings were 581.54 million, a decrease of -29.61%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 603707 stock is "Buy." The 12-month stock price target is ¥11.77, which is an increase of 45.67% from the latest price.

Price Target

¥11.77

(45.67% upside)

Analyst Consensus: Buy

Stock Forecasts